Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Hypophosphatasia →Endocrine & Hormonal

Efzimfotase alfa (ALXN1850) for Hypophosphatasia

FDA decision due
First half of 2027
Exact date not public
Email me the day the FDA decides on Efzimfotase alfa

One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Hypophosphatasia. Unsubscribe anytime.

You'll get, for Hypophosphatasia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

The FDA is expected to decide on Efzimfotase alfa for Hypophosphatasia in the first half of 2027, under a BLA from AstraZeneca (Alexion).

What the FDA is deciding on Efzimfotase alfa for Hypophosphatasia

The FDA is reviewing AstraZeneca (Alexion)'s application to approve Efzimfotase alfa (ALXN1850) for hypophosphatasia.

Next-generation enzyme replacement therapy under priority review for patients aged 2 and older with hypophosphatasia, an inherited disorder of low alkaline phosphatase activity that leaves bones and teeth poorly mineralized. The application rests on 3 Phase 3 trials: MULBERRY met its X-ray primary endpoint in children, CHESTNUT showed children could switch from Strensiq with similar side effects, and HICKORY in adolescents and adults improved the 6-minute walk by 17.05 m over placebo without reaching statistical significance (p=0.1675), which AstraZeneca attributes to a strong placebo response in adult-onset patients.

Alexion's older enzyme, Strensiq, is approved only for pediatric-onset HPP. AstraZeneca has disclosed only that it expects an FDA decision in the first half of 2027.

Who the Efzimfotase alfa decision matters to

Hypophosphatasia (HPP) is a rare inherited disorder in which the body makes too little of an enzyme called alkaline phosphatase, so bones and teeth do not harden properly. It ranges from a life-threatening form in newborns to adults with fractures, pain and early tooth loss.

Strensiq (asfotase alfa), an enzyme replacement injection, is FDA approved for people whose HPP began before age 18, and a longer-acting enzyme, efzimfotase alfa, is under FDA review for everyone aged 2 and older.

Prevalence: Severe HPP that shows up at birth or in infancy affects about 1 in 100,000 live births in Canada, the figure NORD and Soft Bones both use for North America. Milder forms are far more common: European genetic studies estimate them at about 1 in 6,300 people (Orphanet, GeneReviews). AstraZeneca cites a US health-record study putting diagnosed cases at 2.8 per 100,000 people, and says about 80% of people living with HPP are adults. Soft Bones estimates that about 1 in 200 Americans may be a carrier for HPP. See our full Hypophosphatasia page for current treatments, recruiting trials, and community resources.

How Efzimfotase alfa works

Efzimfotase alfa: second-generation recombinant tissue-nonspecific alkaline phosphatase enzyme replacement, engineered for a longer half-life so it can be injected subcutaneously once every 2 weeks. Our full Efzimfotase alfa profile covers how it works, side effects in plain language, and its trial history.

What an approval or a rejection of Efzimfotase alfa would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Where Hypophosphatasia treatment stands today

FDA approved for Hypophosphatasia (1)
Strensiq (asfotase alfa)Enzyme replacement therapysince 2015
Read our full Hypophosphatasia treatment summary

Most HPP studies open today are registries and natural history studies rather than drug trials, and joining one is still worthwhile: Alexion's Global HPP Registry (listed on the Strensiq label, now enrolling by invitation), Duke's natural history study and AstraZeneca's ATLANTIS study of people with a single ALPL variant are all open.

The 3 Phase 3 trials of efzimfotase alfa (HICKORY, MULBERRY and CHESTNUT) finished enrolling; their open-label extensions continue for people already in them, and the FDA is reviewing the drug with a decision expected in the first half of 2027.

The one new drug study recruiting is BioMarin's Phase 1/2a trial of ALE1, an oral pill, which takes adults aged 18 to 50 with a documented ALPL variant who have never had enzyme replacement therapy. As of October 2026 the ALE1 study has sites only in Germany, the UK and New Zealand, and ATLANTIS enrolls only in Russia, so US patients should ask about the registries first.

Ask a metabolic bone specialist which study fits your form of HPP, and bring your ALP, PLP and genetic results to the first call.

The Hypophosphatasia page has every treatment and trial →

Meanwhile, 8 Hypophosphatasia studies are recruiting or not yet recruiting

Whatever the FDA decides here, research on Hypophosphatasia does not stop. Of these, 1 tests a treatment; the others follow patients over time. The most recently updated:

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Patient registry covering many conditions · NCT01793168 · has US sites
Natural History Study of Patients With Hypophosphatasia (HPP)
Observational study, no treatment given · NCT02237625 · has US sites
A Prospective Sub-Study of the Global Hypophosphatasia Registry
Observational study, no treatment given · NCT05234567 · has US sites
See all 8 open studies →

Earlier-stage drugs Trial Friend tracks for Hypophosphatasia

ALE1 · phase 1
Get an email the day the FDA decides on Efzimfotase alfa

We'll email you when the decision is public, with what it means in plain language, and when new trials open for Hypophosphatasia. Unsubscribe anytime.

You'll get, for Hypophosphatasia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Or get every FDA decision, for any condition

One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.

We never share your email. Stop anytime from the link in every email. Privacy policy

Frequently asked questions

When is the FDA decision on efzimfotase alfa for hypophosphatasia?

AstraZeneca expects it in the first half of 2027.

Status: The FDA accepted the application and granted priority review on September 18, 2026.

Exact date: Not disclosed by the sponsor.

AstraZeneca press release

Source: AstraZeneca, September 18, 2026

Did efzimfotase alfa meet its Phase 3 goals?

Two of 3 trials met their main goals; the adult trial did not reach statistical significance.

MULBERRY (children 2 to under 12): X-ray rickets score improved by a median 1.67 versus 0 on placebo, p=0.0003.

CHESTNUT (children switching from Strensiq): similar adverse event rates, bone scores held.

HICKORY (age 12 and up): 6-minute walk improved 17.05 m over placebo, p=0.1675; fatigue improved, nominal p=0.0016.

HICKORY release

Source: AstraZeneca, June 28 and October 11, 2026

Who would efzimfotase alfa be for?

People with hypophosphatasia aged 2 and older, including adults whose disease began in adulthood.

Today: Strensiq is approved only for HPP that began before birth, in infancy or in childhood.

Dosing studied: 1 injection under the skin every 2 weeks.

Source: AstraZeneca, September 18, 2026

When will the FDA decide on Efzimfotase alfa?

AstraZeneca (Alexion) expects a decision in the first half of 2027 but has not given an exact date.

Who disclosed it: AstraZeneca (Alexion). The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: AstraZeneca press release

What is Efzimfotase alfa being reviewed for?

AstraZeneca (Alexion) submitted a BLA for Efzimfotase alfa in Hypophosphatasia.

What to know: Next-generation enzyme replacement therapy under priority review for patients aged 2 and older with hypophosphatasia, an inherited disorder of low alkaline phosphatase activity that leaves bones and teeth poorly mineralized. The application rests on 3 Phase 3 trials: MULBERRY met its X-ray primary endpoint in children, CHESTNUT showed children could switch from Strensiq with similar side effects, and HICKORY in adolescents and adults improved the 6-minute walk by 17.05 m over placebo without reaching statistical significance (p=0.1675), which AstraZeneca attributes to a strong placebo response in adult-onset patients. Alexion's older enzyme, Strensiq, is approved only for pediatric-onset HPP. AstraZeneca has disclosed only that it expects an FDA decision in the first half of 2027.

How it works: Second-generation recombinant tissue-nonspecific alkaline phosphatase enzyme replacement, engineered for a longer half-life so it can be injected subcutaneously once every 2 weeks.

More: the Efzimfotase alfa drug page explains it in plain language.

Is there already an FDA-approved treatment for Hypophosphatasia?

Yes. Trial Friend's drug list includes 1 FDA-approved drug for Hypophosphatasia.

Approved: Strensiq (asfotase alfa).

Check: the Hypophosphatasia page also searches FDA drug labels for approved treatments.

What did the Efzimfotase alfa trials show?

Three Phase 3 trials support the application. MULBERRY (NCT06079359) randomized 29 children in the analysis (30 enrolled per ClinicalTrials.gov) aged 2 to under 12 who had never had Strensiq, 2 to 1 against placebo for 24 weeks; the primary endpoint, the Radiographic Global Impression of Change score for rickets, improved by a median of 1.67 points versus 0 on placebo (median difference 1.67, 95% CI 0.66 to 2.00, p=0.0003), and the Rickets Severity Score also improved (median difference -1.00, p=0.0008), with a 6-minute walk gain of 34.5 m that was not statistically significant.

More: the Efzimfotase alfa drug page has the full trial history and sources.

What are the side effects of Efzimfotase alfa?

No FDA label exists yet, so what is known comes from AstraZeneca's press releases and presentations. The company describes the safety profile as favorable and generally well tolerated across all 3 Phase 3 trials.

More: the Efzimfotase alfa drug page has the safety details reported so far.

Can I get Efzimfotase alfa before the FDA decides?

Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.

Trials: 8 Hypophosphatasia studies are recruiting or not yet recruiting, 1 of them testing a treatment. See them.

Check your fit: Match Me compares your details with every open trial.

Expanded access: your doctor can ask AstraZeneca (Alexion) directly. Registered programs are listed on ClinicalTrials.gov.

How much will Efzimfotase alfa cost?

AstraZeneca (Alexion) has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Efzimfotase alfa decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from AstraZeneca press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.